HOME >> MEDICINE >> NEWS
Sedative may offer new direction in colon cancer treatment

ORLANDO -- A barbiturate once commonly used to treat anxiety may play a role in controlling the spread of colon cancer, say researchers from The University of Texas M. D. Anderson Cancer Center.

Their experimental model of colon cancer -- work done in cell cultures and animal studies -- demonstrates that the drug, Nembutal, can suppress activity in colon cancer cells the same way it inhibits certain kinds of neurotransmissions in the brain and central nervous system.

The results, presented at the annual meeting of the American Association for Cancer Research, suggest a novel approach to treatment of cancers now known to have neurotransmitter receptors on the outside of their cells. That includes, to date, colon and some ovarian cancers.

"This is the first experimental evidence that Nembutal is a potent inhibitor of colon cancer metastasis," says the study's first author, Premal Thaker, M.D., a clinical fellow in the Department of Gynecologic Oncology. "These findings may have therapeutic implications for treatment, but more work needs to be done before we know that."

Scientists have only recently discovered that the surfaces of colon cancer cells are studded with receptors for gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter.

Nerve cells, or neurons, communicate by releasing neurotransmitters. These chemical messengers flow onto other neurons that act as receivers. The neurotransmitter attaches to a slot on the neuron, or receptor site. Once attached, different neurotransmitters either trigger "go" signals that allow the message to be passed on to other cells or produce "stop" signals that prevent the message from being forwarded. GABA is the most common message-altering neurotransmitter in the brain, inhibiting the transfer of other neurotransmitters as well as other chemical signals, such as hormones.

Nembutal is a member of the barbiturate family of drugs commonly known as "downers" -- acting just lik
'"/>

Contact: Julie Penne
jpenne@mdanderson.org
713-792-0655
University of Texas M. D. Anderson Cancer Center
30-Mar-2004


Page: 1 2

Related medicine news :

1. UCSF study offers insight into human circadian rhythms
2. Research offers hope of new treatments for liver damage
3. Portable system offers dialysis patients liberating changes
4. New laparoscopic hysterectomy offers quicker recovery time than traditional surgery
5. UIC offers new weight loss surgery for obese teens
6. Radiologists offer non-surgical treatment for early-stage liver cancer
7. COX-2 product offers good and bad news in test tube strokes
8. Researchers offer emergency workers a lifeline
9. Least protection offered to those most at risk of sudden cardiac death
10. Clinical breast examination offers modest benefit to breast cancer screening program
11. Mayo Clinic discovery on nature of rheumatoid arthritis lung disease may offer patients therapy

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sedative may offer new direction colon cancer treatment

(Date:4/19/2015)... 2015 Carinsurancehints.com has released a new blog ... claim auto insurance benefits . , Drivers who ... all the necessary information for claiming auto insurance benefits. Exchanging ... plan to cover most of the damages. The newly released ... an accident. , Drivers can compare online rates and ...
(Date:4/19/2015)... April 19, 2015 The American Institute ... with PROSHRED Security (“PROSHRED”) to host its second annual, ... shred their personal documents in order to raise funds ... , The June 6th event is being held at ... 2pm local time. The time will vary at select ...
(Date:4/19/2015)... HealthPostures, LLC , a leading ... exhibit it’s pioneering ergonomics products at the Wisconsin Safety ... Council Professional Development Conference and Expo . The products, ... used in volume by call centers, educational organizations, retailers, ... clamp to a desk, the TaskMate Go 6350 and ...
(Date:4/18/2015)... Carinsurancesavings.biz has released a new blog post explaining ... Spring. , Spring can be a great season ... sure they compare the newest policies before deciding on ... about Spring car insurance offers by reading the newly ... becoming more and more popular. Many insurance brokerage websites ...
(Date:4/18/2015)... Insuranceautoquote.info has released a new blog post ... . , Clients can review important auto insurance ... environment provides important advantages for clients who need affordable ... do not have coverage for their vehicles can purchase ... or hour. Many agencies offer important discounts and drivers ...
Breaking Medicine News(10 mins):Health News:An Online Guide About Claiming Auto Insurance Benefits After an Accident 2Health News:2015 Annual Nationwide "Shred Cancer" Shredding Event 2Health News:HealthPostures' TaskMate Products to be Exhibited at the Wisconsin and Iowa-Illinois Safety Conferences 2Health News:Auto Insurance Plans Are Cheaper During Spring! 2Health News:Clients Can Review Car Insurance Quotes Online To Find Low Cost Offers! 2
(Date:4/17/2015)... - The issue: In consultation ... lot (lot 710535) of Clavulin-400 (70mL) after receiving a complaint ... in one bottle of the  product. No other lots of ... Clavulin-400 is an oral antibiotic used in adults and children ... Clavulin-400 comes as a powder in bottles and is mixed ...
(Date:4/17/2015)... , April 17, 2015 Contego ... Integrated Embolic Protection™ filter platform for angioplasty balloon ... a $5.6 million Series B financing round led ... firm with a focus on medical devices, biopharmaceuticals, ... round also included Mountain Group Partners, Lookout Capital ...
(Date:4/17/2015)... April 17, 2015  Regulatory leaders in the pharmaceutical ... discussion draft called "21 st Century Cures." ... be taken up by Congress soon and if enacted ... device products are developed and marketed in ... companies have begun to consider how the proposed changes ...
Breaking Medicine Technology:Advisory - Clavulin-400 liquid oral antibiotic: One lot recalled after glass pieces found in one bottle 2Contego Medical Closes $5.6 Million in Series B Funding 2Contego Medical Closes $5.6 Million in Series B Funding 321st Century Cures: A Regulatory Game-Changer for the Pharmaceutical Industry 2
Cached News: